■头孢呋辛在预防和治疗细菌感染方面发挥了至关重要的作用。然而,不同给药方案和给药途径的不良事件差异尚不清楚.
■本研究旨在调查头孢呋辛的上市后安全性,特别是关于配方和路线。
■使用来自食品和药物管理局不良事件报告系统数据库的数据进行头孢呋辛的回顾性药物警戒研究。
■研究了头孢呋辛的临床特征和合并用药。根据四种不成比例算法鉴定头孢呋辛的不良事件信号。进一步检查了头孢呋辛在制剂和途径之间的信号差异。
■共发现1810份与头孢呋辛相关的不良事件报告,并检测到181个头孢呋辛相关信号.与片剂相比,注射更可能导致首选术语“血压降低”和“过敏性休克”。此外,头孢呋辛眼内给药时,系统器官类别\'眼部疾病\'显着增加,强调注意眼部毒性的重要性。
与头孢呋辛相关的不良事件在不同的制剂和途径上有显著差异,在临床使用中值得特别注意。
头孢呋辛上市后安全问题。
■头孢呋辛是一种常用的抗生素。本研究使用食品和药物管理局不良事件报告系统数据库调查头孢呋辛的安全性。
■我们分析了头孢呋辛的临床特征和合并用药。然后,我们检测到头孢呋辛的信号.我们进一步检查了头孢呋辛在制剂和途径之间的信号差异。
■我们检索了1810份报告,并确定了与头孢呋辛相关的181个信号。与片剂相比,注射引起血压下降和过敏性休克的可能性较高。此外,头孢呋辛眼内给药增加了患眼部疾病的可能性。
■与头孢呋辛相关的信号在不同的制剂和途径中显著不同,在临床使用中值得特别注意。
UNASSIGNED: Cefuroxime has played a crucial role in the prevention and treatment of bacterial infections. However, the differences in adverse events across formulations and routes remain unclear.
UNASSIGNED: This study aimed to investigate the post-marketing safety of cefuroxime, particularly concerning formulations and routes.
UNASSIGNED: A retrospective pharmacovigilance study of cefuroxime was conducted using the data from Food and Drug Administration Adverse Event Reporting System database.
UNASSIGNED: The clinical characteristics and concomitant drugs reported with cefuroxime were investigated. Adverse event signals of cefuroxime were identified based on four disproportionality algorithms. The signal differences of cefuroxime across formulations and routes were further examined.
UNASSIGNED: A total of 1810 adverse event reports associated with cefuroxime were identified, and 181
cefuroxime-associated signals were detected. Compared with tablets, injections were more likely to cause preferred terms \'blood pressure decreased\' and \'anaphylactic shock\'. In addition, system organ class \'eye disorders\' significantly increased when cefuroxime was administered intraocularly, underscoring the importance of exercising caution regarding ocular toxicity.
UNASSIGNED: The adverse events associated with cefuroxime were significantly different across formulations and routes, which deserve special attention in clinical use.
Post-marketing safety concerns with
cefuroxime.
UNASSIGNED: Cefuroxime is a commonly used antibiotic. This study investigated the safety of cefuroxime using Food and Drug Administration Adverse Event Reporting System database.
UNASSIGNED: We analyzed the clinical characteristics and concomitant drugs reported with cefuroxime. Then, we detected the signals of
cefuroxime. We further examined the signal differences of cefuroxime across formulations and routes.
UNASSIGNED: We retrieved 1810 reports and identified 181 signals associated with cefuroxime. In comparison to tablets, injections had a higher likelihood of causing decreased blood pressure and anaphylactic shock. Furthermore, the administration of cefuroxime intraocularly increased the possibility of experiencing eye disorders.
UNASSIGNED: The signals associated with cefuroxime were significantly different across formulations and routes, which deserve special attention in clinical use.